All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

NMPA Accepts and Grants Priority Review to NDA for Sovleplenib in Primary Immune Thrombocytopenia

January 11th 2024

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

January 11th 2024

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

First-in-Class YAP/TEAD Inhibitor Demonstrates Early Efficacy Targeting Hippo Pathway

January 11th 2024

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

Life With “The Most Extraordinary Job”

January 11th 2024

Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.

FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia

January 10th 2024

The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.

Engineered Bone Marrow Shows Preclinical Potential in Osteosarcoma

January 10th 2024

R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.

Adagrasib Approved in Europe for Pretreated KRAS G12C+ Advanced NSCLC

January 10th 2024

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 10th 2024

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

January 10th 2024

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.

Alana Welm, PhD, Receives Award For Breast Cancer Research

January 10th 2024

Alana Welm, PhD, received the 2023 American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research.

Wakelee Addresses NSCLC Treatment Considerations From Every Angle

January 10th 2024

Heather Wakelee, MD, discusses the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Allegheny Health Network Oncology Experts Dive Into Updates Within the Gynecologic Oncology Space

January 10th 2024

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

NCCN Adds Nirogacestat to Guidelines for Patients With Soft Tissue Sarcoma

January 9th 2024

The NCCN has updated its guidelines for soft tissue sarcoma to include nirogacestat as a systemic therapy option for patients with desmoid tumors.

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors

January 9th 2024

Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL

January 9th 2024

BRL-201 had a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma.

Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant

January 9th 2024

Thomas G. Martin, MD, has received a grant from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma.

FDA Grants Priority Review to Tisotumab Vedotin sBLA for Recurrent or Metastatic Cervical Cancer

January 9th 2024

The FDA has granted priority review to a sBLA seeking to convert the accelerated approval of tisotumab vedotin to full approval in select patients with cervical cancer.

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

January 9th 2024

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

Combination Regimens Stir Excitement in Advanced RCC

January 9th 2024

Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

January 9th 2024

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.